The US generic drugs market revenue has exhibited robust growth between 2020 and 2025, climbing from $75,000 Million in 2020 to an estimated $101,500 Million in 2025, and is projected to reach $174,800 Million by 2035. Continued demand for affordable medication and consistent patent expirations fuel this uptrend, supported by expanding biosimilar and complex generic portfolios from leading manufacturers. The market is anticipated to continue on this upward trajectory as healthcare stakeholders seek cost savings and broaden patient access. Year-on-year increases reflect both changing policy landscapes and new product introductions.
Read More - https://bussinessinsights.com/research-report/us-generic-drugs
Cardiology remains the leading application area for generic drugs in 2025, driven by the high prevalence of cardiovascular diseases and the need for cost-effective long-term treatments. Oncology is the fastest-growing segment, with biosimilars and complex generics making cancer therapies more accessible. Anti-infectives, CNS, and respiratory drugs also command significant market shares, as generics play an essential role in both acute and chronic care settings. The following breakdown demonstrates the stronghold of cardiology and oncology applications, as generics deliver value across all therapeutic categories.
Request Free Sample- https://bussinessinsights.com/request/telecommunication/us-generic-drugs
Who are the key players in US Generic Drugs industry?
Major players include Teva Pharmaceuticals, Sandoz (a division of Novartis), Viatris (formerly Mylan), Lupin Pharmaceuticals, and Amneal Pharmaceuticals. These companies focus on producing cost-effective generic alternatives to brand-name drugs, broadening access to vital medications in the US healthcare market.
What is the US Generic Drugs growth?
The US generic drugs market has experienced steady growth, with increasing demand for affordable treatment options. In 2023, companies like Teva Pharmaceuticals reported rising generic sales due to patent expirations and cost-containment measures, driving revenue growth in the sector.
Which segment accounted for the largest US Generic Drugs share?
Oral generic drugs represent the largest market share within the US generic drugs sector. This dominance is due to the high volume of prescribed tablets and capsules for chronic conditions such as cardiovascular diseases and diabetes, providing ease of manufacturing and wide patient acceptance.
Thanks & Regards,
Manisha C
sales [at] bussinessinsights.com